Speakers
Keynote Speakers
Carl June, MD
Richard W. Vague Professor in Immunotherapy; Director, Center for Cellular Immunotherapies, Perelman School of Medicine Director, Parker Institute Cancer Immunotherapy; University of Pennsylvania USA Short Bio - click hereCarl June, MD
Richard W. Vague Professor in Immunotherapy; Director, Center for Cellular Immunotherapies, Perelman School of Medicine Director, Parker Institute Cancer Immunotherapy; University of Pennsylvania USANicholas Restifo, MD
Executive VP, Research, Lyell Immunopharma Inc.,USAStanley Riddell, MD
Director, Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Professor, Department of Medicine at the University of Washington USAStanley Riddell, MD
Director, Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Professor, Department of Medicine at the University of Washington USASpeakers & Session Chairs
John Anderson, PhD
GOSHCC Professor of Experimental Paediatric Oncology Honorary Consultant Oncologist UCL Great Ormond Street Institute of Child Health, UK Short Bio - click hereJohn Anderson, PhD
GOSHCC Professor of Experimental Paediatric Oncology Honorary Consultant Oncologist UCL Great Ormond Street Institute of Child Health, UKRicardo Baptista, PhD
Director, Process and Analytical Development, Cellectis, France Short Bio - click hereRicardo Baptista, PhD
Director, Process and Analytical Development, Cellectis, FranceAdi Barzel, PhD
President of the Israeli Society for Gene and Cell Therapy (ISGCT), ICLE Conference Chair, Senior lecturer at Tel-Aviv University, Israel Short BioAdi Barzel, PhD
President of the Israeli Society for Gene and Cell Therapy (ISGCT), ICLE Conference Chair, Senior lecturer at Tel-Aviv University, IsraelPaul Beavis, PhD
Group Leader, Peter MacCallum Cancer Centre, AustraliaMichal Besser, PhD
Head of Laboratory Ella Lemelbaum Institute for Immuno Oncology Sheba Medical Center, Israel; Assistant Professor Dept. of Microbiology and Immunology School of Medicine, Tel Aviv University, Israel Short Bio - click hereMichal Besser, PhD
Head of Laboratory Ella Lemelbaum Institute for Immuno Oncology Sheba Medical Center, Israel; Assistant Professor Dept. of Microbiology and Immunology School of Medicine, Tel Aviv University, IsraelSimon Briggs, PhD
Senior Product Steward, Novartis Pharma Ag. SwitzerlandJennifer Brogdon, PhD
Executive Director, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, USA Short BioJennifer Brogdon, PhD
Executive Director, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, USAChristian Buchholz, PhD
Head of Molecular Biotechnology and Gene Therapy Paul-Ehrlich-Institute, Germany Short BioChristian Buchholz, PhD
Head of Molecular Biotechnology and Gene Therapy Paul-Ehrlich-Institute, GermanyDirk Busch, MD
Director at the Institute for Med. Microbiology, Immunology and Hygene Technical University of Munich, GermanyDirk Busch, MD
Director at the Institute for Med. Microbiology, Immunology and Hygene Technical University of Munich, GermanyYaron Carmi, PhD
Senior Lecturer, Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Israel Short BioYaron Carmi, PhD
Senior Lecturer, Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, IsraelLaurence Cooper, MD, PhD
CEO, ZioPharm, USALaurence Cooper, MD, PhD
CEO, ZioPharm, USASusan Dunne, PhD
R&D Scientist Immunology, Avectas Ltd., IrelandSusan Dunne is an R&D Scientist in the Immunology Group at Avectas. Susan holds a PhD in Molecular Immunology from Maynooth University and her thesis focused on immune cell signalling. She also has a MSc in Molecular Medicine from Trinity College Dublin. At Avectas, Susan’s work focuses on demonstrating functionality of Soluporated T cells. She is heavily involved in multiple partnership projects at Avectas which are based around the delivery of gene editing cargos to T cells.
Susan Dunne, PhD
R&D Scientist Immunology, Avectas Ltd., IrelandSeth Ettenberg, PhD
Chief Scientific Officer, UNUM Therapeutics, USASeth Ettenberg, PhD
Chief Scientific Officer, UNUM Therapeutics, USAJason Fontenot, PhD
Senior Vice President, Cell Therapy, Sangamo, FranceDinorah Friedmann-Morvinski, PhD
Senior Lecturer, Tel Aviv University, IsraelDinorah Friedmann-Morvinski, PhD
Senior Lecturer, Tel Aviv University, IsraelSian Harding, PhD
Board Member of the British Society of Gene and Cell Therapy, Professor of Cardiac Pharmacology Director, BHF Cardiovascular Regenerative Medicine Centre Campus Director, Imperial Hammersmith and White City, NHLI, Imperial College London, UKSian Harding is Director of the Imperial British Heart Foundation Cardiovascular Regenerative Medicine Centre. Her work has centered on the myocardium in heart failure, especially beta-adrenergic mechanisms. She was Scientific PI on the first UK Gene therapy Trial in LVAD patients, aimed at improving cardiac contractility. She is now studying the pluripotent stem cell-derived cardiomyocyte, both for disease modelling and cardiac repair. Professor Harding is former President of the European Section of the International Society for Heart Research and is on the Board of the British Society of Gene and Cell Therapy.
Sian Harding, PhD
Board Member of the British Society of Gene and Cell Therapy, Professor of Cardiac Pharmacology Director, BHF Cardiovascular Regenerative Medicine Centre Campus Director, Imperial Hammersmith and White City, NHLI, Imperial College London, UKMichael Hudecek, MD
Director, CAR-T Programme Hospital of the University of Würzburg, Germany Short Bio - click hereMichael Hudecek, MD
Director, CAR-T Programme Hospital of the University of Würzburg, GermanyKlaus Kuehlcke, PhD
CEO, BioNTech IMFS GmbH, GermanyDan MacLeod, PhD
Director, Cell Therapy Discovery, Precision BioSciences Inc., USADan MacLeod, PhD
Director, Cell Therapy Discovery, Precision BioSciences Inc., USAChris Mann, PhD
Director, Field Applications Scientist Team, Maxcyte, USAR. Scott McIvor, PhD
Chief Development Officer, Immusoft Corporation; Professor Genetics, Cell Biology, and Development, University of Minnesota, USA Short Bio - click hereR. Scott McIvor, PhD
Chief Development Officer, Immusoft Corporation; Professor Genetics, Cell Biology, and Development, University of Minnesota, USAChris Peterson, PhD
Research Assistant Professor, University of Washington Staff Scientist, Fred Hutchinson Cancer Research Center, USAChris Peterson is a Research Assistant Professor at the University of Washington School of Medicine, and a Staff Scientist in the lab of Dr. Hans-Peter Kiem at the Fred Hutchinson Cancer Research Center in Seattle. His work focuses on approaches to gene-modify hematopoietic stem cells and T-cells, and evaluate their function in the nonhuman primate model. The majority of his work utilizes NHP models of HIV infection, which are designed to inform therapies for infectious as well as malignant diseases. He is a member of defeatHIV, one of three Martin Delaney HIV Cure Collaboratories funded by the U.S. National Institutes of Health
Chris Peterson, PhD
Research Assistant Professor, University of Washington Staff Scientist, Fred Hutchinson Cancer Research Center, USAWaseem Qasim, PhD
Professor of Cell and Gene Therapy, Institute of Child Health, UCL Consultant in Paediatric Immunology, Reader in Cell and Gene Therapy at Great Ormond Street Hospital for Children NHS Trust, UKWaseem Qasim, PhD
Professor of Cell and Gene Therapy, Institute of Child Health, UCL Consultant in Paediatric Immunology, Reader in Cell and Gene Therapy at Great Ormond Street Hospital for Children NHS Trust, UKYoram Reiter, PhD
Head Laboratory of Molecular Immunology and Cancer Immunotherapy, Dean, Faculty of Biology, Technion-Israel Institute of Technology, IsraelYoram Reiter, PhD
Head Laboratory of Molecular Immunology and Cancer Immunotherapy, Dean, Faculty of Biology, Technion-Israel Institute of Technology, IsraelSaskia Roesch, PhD
Global Product Manager, T Cell Immunology, Miltenyi Biotec, GermanySaskia Roesch (Ph.D.) received her doctoral degree in Biology from the University of Heidelberg/DKFZ, Germany, in 2017. She continued her studies in Cancer Immunotherapy as a postdoctoral fellow at the University Hospital in Heidelberg, Germany, before joining Miltenyi Biotec as a Global Product Manager for T Cell Immunology.